Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Related Content

Brief Version
Full Version

Non-Nucleoside Reverse Transcriptase Inhibitors

Etravirine (Intelence, ETR)

Last Updated: December 24, 2019; Last Reviewed: December 24, 2019

Excerpt from Table 8

Excerpt from Table 8
Generic Name
(Abbreviation)
Trade Name		 Formulation Dosing Recommendationsa Use in Pregnancy
Etravirine
(ETR)
Intelence 		Tablets:
  • 25 mg
  • 100 mg
  • 200 mg
For patients who are unable to swallow tablets whole, the tablets may be dispersed in a glass of water. 		Standard Adult Dose:
  • ETR 200 mg twice daily with food
Pregnancy
PKs in Pregnancy:
  • PK data in pregnancy suggest 1.2-fold to 1.6-fold increases in ETR exposure during pregnancy.
Dosing in Pregnancy:
  • No change in dose indicated.
 Placental transfer varies; it is usually in the moderate to high categories, ranging from 0.19–4.25.b

Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.
a Individual ARV drug doses may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Antiretroviral Guidelines, Appendix B, Table 10).

b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
          High: >0.6
          Moderate: 0.3–0.6
          Low: <0.3

Key: ARV = antiretroviral; ETR= etravirine; PK = pharmacokinetic

Download Guidelines

Related Content

Email News letter Updates